Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer's Association International Conference (AAIC), indicating that ... Read More
Lilly, Innovent Biologics expand licensing deal for blood cancer drug Tyvyt
Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed ... Read More
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers
Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and ... Read More
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More
Eli Lilly completes $8bn acquisition of Loxo Oncology to expand oncology portfolio
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly ... Read More